The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2025 | Future directions for the ASPEN-06 trial in advanced gastric cancer
Kohei Shitara, MD, National Cancer Center Hospital East, Kashiwa, Japan, considers the potential progression of the randomized Phase II/III ASPEN-06 study (NCT05002127), including the possibility of a Phase III trial focusing on patients with persistent human epidermal growth factor receptor 2 (HER2) positivity using fresh biopsy or circulating tumor DNA (ctDNA). Additionally, ASPEN-06 highlights the potential of CD47 blockade in solid tumours, a benefit demonstrated for the first time in a randomized study. This interview took place at the ASCO GI Cancers Symposium 2025 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
